Open AccessS208: EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL
Author(s) -
Zelenetz A.,
Jurczak W.,
Ribrag V.,
Linton K.,
Collins G.,
LopézJiménez J.,
Reddy N.,
Mengarelli A.,
Phillips T.,
Musuraca G.,
Sheehy O.,
Li J.,
Xu W.,
Azoulay M.,
Ghalie R.,
Zinzani P. L.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843724.38671.cf
Subject(s) - medicine , dosing , adverse effect , rituximab , population , follicular lymphoma , tolerability , refractory (planetary science) , nausea , debulking , cohort , oncology , surgery , lymphoma , ovarian cancer , cancer , astrobiology , physics , environmental health